Dr. Baliga's 'Podkasts for Curious Docs'
🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬 📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare’s first autopsy to myosin inhibitors, AI diagnostics, and gene therapy. 💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read. 📉 SCD prevention, 🫀 LVOT obstruction, 🧪 MYBPC3/MYH7 mutations, 🧬 proteomics, and more. 🔗 Essential reading for cardiologists, geneticists, and...
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥 ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions 🔬 APOC3 inhibition emerges as a game-changer in lipidology. 📖 ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals #Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI...
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—“just sitting” 🧘♂️—where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. 🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again. 📚 Published in JAMA, presented at #ESC2025 🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expanding role in cardiometabolic HFpEF 🫀 #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️. 🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates — but will it move the needle on outcomes? #AFib #StrokePrevention #RemoteMonitoring #ECG #Cardiology #RCT #JAMA #DigitalHealth #Geriatrics 🧓📉
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠. 📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most. 📝 Editorial: Recommends shared decision-making 🤝 & individualized rhythm monitoring. 📚 A potential shift in post-ablation care. 🔗 #AFib #Anticoagulation #EPTrials #CardioTwitter #StrokePrevention #JAMA...
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? 💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75) 🧠 Key Takeaway: Routine screening isn’t broadly warranted—but targeted testing in high-risk AMI patients may be the smarter path forward. 📊...
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. 💬 Let’s rethink how we label, risk-stratify, and treat. 📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine...
info_outlineDr. Baliga's 'Podkasts for Curious Docs'
🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨ #Leadership #Philosophy #History #Confucianism
info_outlineZhuang Zhou, also known as Zhuangzi, was an influential 4th-century BCE Chinese philosopher during the Warring States period.
As a foundational figure of Taoism, he authored the Zhuangzi, a text known for its profound philosophical insights, parables, and critiques of societal norms, emphasizing personal freedom and harmony with the Tao.
His ideas remain central to Chinese philosophy and continue to inspire discussions on ethics, metaphysics, and human nature.